Loading clinical trials...
Loading clinical trials...
A Randomized Study of Haploidentical Lymphocytes With Nivolumab and Intermediate Dose Cytarabine Versus Nivolumab and Intermediate Dose Cytarabine as Consolidation Treatment in Older Adults With Acute Myeloid Leukemia.
Conditions
Interventions
Cytarabine
Nivolumab
+3 more
Locations
1
Russia
Boris V Afanasyev, MD, Prof.
Saint Petersburg, Russia
Start Date
June 30, 2017
Primary Completion Date
September 30, 2018
Completion Date
September 30, 2018
Last Updated
April 5, 2019
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT06994676
NCT04628026
Lead Sponsor
St. Petersburg State Pavlov Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions